

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 1, 2006

Access Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware 0-9314 83-0221517

(State of Incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)

2600 Stemmons Freeway, Suite 176, Dallas, Texas 75207

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (214) 905-5100

Item 5.02 Departure of Directors or Principal Officers;
Election of Directors;
Appointment of Principal Officers

On September 1, 2006, the election became effective of a new board member - Mark J. Ahn, PhD - to the Access Pharmaceuticals, Inc. Board of Directors.

Dr. Ahn is currently President and CEO of Hanna Biosciences, Inc., a South San Francisco, CA - based biopharmaceutical company which acquires, Develops and commercializes innovative products to advance cancer care. Previously to Hanna, Dr. Ahn served as Vice President, Hematology and Corporate officer at Genentech, Inc. Prior to Genentech, Dr. Ahn held a Series of positions of increasing responsibility at Bristol-Meyers Squibb Company, Amgen, Inc. and FMC Corporation.

Effective September 1, 2006, Max Link, PhD resigned from the Board of Directors.

A press release is attached as Exhibit 99.1 to this report and is Incorporated herein by this reference, in which the Company announced its new director Mark Ahn, PhD and the resignation of its director Max Link, PhD.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Access Pharmaceuticals, Inc.
(Registrant)

By: /s/ Stephen B. Thompson

Stephen B. Thompson
Vice President and
Chief Financial Officer

Dated September 7, 2006

3

EXHIBIT INDEX

Exhibit
Number Description

99.1 Press Release, dated September 5, 2006

LOGO

ACCESS NEWS

Contact: Company
Stephen B. Thompson
Vice President & CFO

Contact: Investor Relations
Donald C. Weinberger
Wolfe Axelrod Weinberger
Associates, LLC
(212) 370-4500

(214) 905-5100

ACCESS PHARMACEUTICALS, INC. ANNOUNCES BOARD CHANGES

DALLAS, TEXAS, September 5, 2006 -- ACCESS PHARMACEUTICALS, INC. (ACCP.OB) today announced the appointment of Mark J. Ahn, Ph.D. to the Board of Directors of the Company. In addition, Max Link, Ph.D., a board member since 1996, has announced his resignation.

Dr. Ahn is currently President and Chief Executive Officer of Hana Biosciences, Inc., a South San Francisco, CA-based biopharmaceutical company which acquires, develops, and commercializes innovative products to advance cancer care.

Prior to Hana, Dr. Ahn served as Vice President, Hematology and corporate officer at Genentech, Inc. where he was responsible for commercial and clinical development of the Hematology franchise which surpassed \$1 billion in revenues, achieved the #1 oncology therapeutic position in the US, and was recognized as the #1 sales and marketing team in the biopharmaceutical industry by Product Management Today. Prior to Genentech, Dr. Ahn held a series of positions of increasing responsibility at Bristol-Myers Squibb Company, Amgen, Inc., and FMC Corporation in strategy, general management, sales & marketing, business development, and finance.

"I am excited by the opportunity to assist Access in advancing its drug platform and, particularly, its cancer care product platform. My experience in this area could be of great benefit in helping Access realize its goals and aspirations," noted Dr. Ahn.

Commenting on the appointment, Rosemary Mazanet, M.D. Ph.D., Acting CEO of Access, stated, "Mark's focus on commercializing advanced cancer care products will be important as Access continues to develop its polymer platinate cancer drug, ProLindac(TM). His experience in developing a broad array of therapeutic products to market will complement our board of directors."

Speaking about the resignation of Dr. Link, Dr. Mazanet stated, "We are grateful for Max's contributions to the board, over the last 10 years, and we wish him well in his future endeavors."

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the treatment of patients with mucositis. The Company also has other advanced drug delivery technologies including vitamin mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including statements relating to the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission.

###